GSK Q2 2025 Financial Performance and Pipeline Progress

SEC Filing 6-K (0001654954-25-008641)

GSK reported strong Q2 2025 financial results, with total sales of £8.0 billion, a 1% increase at AER and 6% at CER. Specialty Medicines drove growth, with sales up 15% to £3.3 billion, led by Respiratory, Immunology & Inflammation, Oncology, and HIV. Vaccines sales increased by 9% to £2.1 billion, supported by Shingrix and Arexvy. Core operating profit rose 12% to £2.6 billion, and core EPS grew 15% to 46.5p. GSK expects to meet the upper end of its 2025 guidance, with turnover growth of 3-5%, core operating profit growth of 6-8%, and core EPS growth of 6-8%. The company also highlighted progress in its pipeline, with 5 major new product approvals expected in 2025, including Blenrep for multiple myeloma and depemokimab for asthma. GSK continues to invest in R&D, with 14 key opportunities expected to launch between 2025 and 2031.